Investor Relations

The Share

The Diamyd Medical share is traded on Nasdaq First North (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North

Nasdaq First North is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Annual Report

  October 25, 2018

CEO Comments

Read More
  Quarterly Report 3, June 26, 2019

Dear Shareholders and readers

This June, over 15,000 representatives from industry, health care and academia within the diabetes field, gathered in San Francisco for the 79th Scientific Sessions organized by the American Diabetes Association (ADA). The conference marked a significant step forward for the field and strengthens the case for Diamyd Medical’s mission to cure type 1 diabetes.
The results have been received with great interest during partner discussions and show the potential of intralymphatic injections of Diamyd®.
Ulf Hannelius, President and CEO

Calendar

  
August 28 − August 29, 2019
LSX Nordic Congress
Stockholm, Sweden
October 2, 2019
Year-End Report
Year-End Report 2018/2019
October 31, 2019
Annual Report
Annual Report 2018/2019
November 21, 2019
Annual General Meeting
Annual General Meeting 2018/2019
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 29, 2019

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 556 223 7 333 040 14.30 35.69
Avanza Pension 8 485 931 12.27 9.21
Lindkvist, Bertil 6 160 000 8.91 6.68
Nordnet Pension 2 698 435 3.90 2.93
Swedbank Försäkring 1 083 758 1.57 1.18
Hansen, Patrik 1 030 000 1.49 1.12
Konstruktions o Försäljningsaktiebolag 740 000 1.07 0.80
Arandi Development AB 505 000 0.73 0.55
Relbo AB 475 550 0.69 0.52
Schelé, Sven 460 000 0.67 0.50
Remaining shareholders 37 641 859 54.4 40.80
Total 2 556 223 66 613 573 100.0 100.0

Annual Report

  October 25, 2018  
Download

Contact Us

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©